share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  2024/09/10 11:03

Moomoo AI 已提取核心訊息

ZyVersa Therapeutics, Inc., a biopharmaceutical company, has achieved a significant milestone with the Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) as of 5:00 P.M. on September 9, 2024. The notice pertains to Form S-3, which is commonly used by companies to register securities for potential future offerings. This development indicates that ZyVersa Therapeutics has met the necessary regulatory requirements to move forward with the registration of its securities, as documented under file number 333-281913. The effectiveness of the form is a crucial step for the company, potentially paving the way for future capital raising activities through the sale of registered securities.
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has achieved a significant milestone with the Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) as of 5:00 P.M. on September 9, 2024. The notice pertains to Form S-3, which is commonly used by companies to register securities for potential future offerings. This development indicates that ZyVersa Therapeutics has met the necessary regulatory requirements to move forward with the registration of its securities, as documented under file number 333-281913. The effectiveness of the form is a crucial step for the company, potentially paving the way for future capital raising activities through the sale of registered securities.
生物製藥公司ZyVersa Therapeutics, Inc. 已經取得了重要的里程碑,美國證券交易委員會(SEC)在2024年9月9日下午5點發布了有效通知。該通知涉及S-3表格,這是公司常用的表格,用於註冊未來可能的證券發行。這一進展表明ZyVersa Therapeutics已經滿足了前進註冊其證券的必要監管要求,文件號爲333-281913。表格的有效性對公司來說是一個關鍵的步驟,可能爲通過出售已註冊的證券進行未來的資本籌集活動鋪平道路。
生物製藥公司ZyVersa Therapeutics, Inc. 已經取得了重要的里程碑,美國證券交易委員會(SEC)在2024年9月9日下午5點發布了有效通知。該通知涉及S-3表格,這是公司常用的表格,用於註冊未來可能的證券發行。這一進展表明ZyVersa Therapeutics已經滿足了前進註冊其證券的必要監管要求,文件號爲333-281913。表格的有效性對公司來說是一個關鍵的步驟,可能爲通過出售已註冊的證券進行未來的資本籌集活動鋪平道路。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息